- Home
- NMIH vs LEGN Comparison
NMIH vs LEGN Comparison
Compare NMIH & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NMIH | LEGN |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2013 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NMIH | LEGN |
|---|---|---|
| Price | $38.76 | $18.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $49.14 | $45.62 |
| AVG Volume (30 Days) | 665.4K | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.06 | N/A |
| EPS | ★ 2.66 | N/A |
| Revenue | ★ $706,440,000.00 | N/A |
| Revenue This Year | $6.80 | $39.39 |
| Revenue Next Year | $5.24 | $23.72 |
| P/E Ratio | $14.87 | ★ N/A |
| Revenue Growth | ★ 8.52 | N/A |
| 52 Week Low | $34.84 | $16.24 |
| 52 Week High | $46.74 | $37.50 |
Technical Indicators
Market Signals| Indicator | NMIH | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 47.68 |
| Support Level | $36.13 | $17.81 |
| Resistance Level | $39.62 | $19.92 |
| Average True Range (ATR) | 1.09 | 0.73 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 53.66 | 47.64 |
Price Performance
Historical ComparisonAbout NMIH NMI Holdings Inc.
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.